SCHEMBL401708

SCHEMBL401708

COC(=O)c1cc(C)c(O)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
XDH P47989 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
GAA P10253 1/20 0.55
NFKB1 P19838 1/20 0.55
GFER P55789 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
FUT7 Q11130 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA7 P43166 3/20 0.52
CA9 Q16790 3/20 0.52
CA14 Q9ULX7 3/20 0.52
ESR1 P03372 3/20 0.46
ACLY P53396 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL282150 0.88 KDM4E (0.63) KDM4EXDHTDP1LMNAPOLB
Water SCHEMBL7957219 0.86 KDM4E (0.61) KDM4EXDHTDP1LMNAPOLB
SCHEMBL198717 0.86 KDM4E (0.65) KDM4EXDHTDP1LMNAPOLB
SCHEMBL1420175 0.83 LMNA (0.74) KDM4EXDHTDP1LMNAPOLB
SCHEMBL3595464 0.82 ESR1 (0.59) TDP1LMNAL3MBTL1CA12CA1
SCHEMBL3353446 0.81 LMNA (0.77) KDM4EXDHTDP1LMNAPOLB
SCHEMBL3555140 0.80 CA1 (0.54) KDM4EXDHTDP1LMNAPOLB
SCHEMBL4512198 0.80 CA1 (0.54) KDM4EXDHTDP1LMNAPOLB
SCHEMBL24481314 0.80 ALDH1A1 (0.53) KDM4EXDHTDP1LMNAPOLB
SCHEMBL22021808 0.80 KDM4E (0.53) KDM4EXDHTDP1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022111526-A1 BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2022-06-02 WO disclosed
WO-2014063199-A1 ORGANIC COMPOUNDS AKAAL PHARMA PTY LTD (AU) 2014-05-01 WO disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
WO-2007072041-A1 THERAPEUTIC COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-06-28 WO disclosed
WO-2007072041-A1 THERAPEUTIC COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-06-28 WO disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA KDM4E 2908/4885XDH 1927/4885TDP1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.